Cyclic Glycine-Proline (cGP)

🔹 What is Cyclic Glycine-Proline (cGP)?

Class: Naturally occurring cyclic dipeptide; a metabolite of IGF-1. Mechanism:

• Formed endogenously as IGF-1 is broken down in the body — it isn’t a synthetic analogue of anything, it’s a natural byproduct of IGF-1 metabolism.
• Regulates the bioavailability of IGF-1 by modulating IGF-binding proteins (IGFBPs), effectively acting as a rheostat on how much free, active IGF-1 reaches tissues — including the brain.
• Because IGF-1 signaling supports neuronal survival, synaptic plasticity, and vascular health in the brain, cGP’s role in fine-tuning that signaling is the basis for its neuroprotective research interest.
• Animal studies have examined cGP’s effects on memory and learning, and its potential to mitigate some of the downstream effects associated with amyloid plaque accumulation.

Primary focus:

• Cognitive support and neuroprotection through modulation of endogenous IGF-1 activity.
• Early-stage research interest in memory, age-related cognitive decline, and neurodegenerative disease models.

---

🔹 Oral Dosage Range studied/used in research: Animal and early human research has explored oral dosing, since cGP appears more stable against enzymatic degradation than many linear peptides due to its cyclic structure. Notes: Oral administration has been the more commonly studied route for this compound specifically because of that relative stability, though formal human dosing standards are not established.

---

🔹 Injectable / Subcutaneous Dosage Range: Subcutaneous administration has also been explored in research settings, particularly in animal models examining central nervous system effects. Rationale: Systemic or subcutaneous delivery is sometimes used in research to more directly assess dose-response relationships, bypassing variability in oral absorption.

---

🔹 Cycle Length Common cycle length: Not well established outside of research protocols; cognitive-support use in practice tends to follow longer, ongoing patterns (8–12 weeks or more) rather than short bursts, given its mechanism is about steady modulation of IGF-1 signaling rather than an acute pulse. Off-cycle: No standardized washout period has been defined; this remains an early-stage research compound.

---

✅ Educational Integration Example

• Example protocol: Given the early-stage nature of the human data, there isn’t an established, well-validated protocol to point to here — most available information comes from animal and preclinical research rather than routine practice.
• Sometimes discussed alongside other cognitive-support peptides (such as Dihexa or Semax) in broader nootropic-adjacent stacking conversations, though the two act through distinct mechanisms.

---

🔹 Stacking Strategy (Educational / Complementary) Since cGP works by modulating IGF-1 bioavailability rather than acting as a direct GH secretagogue or classical nootropic, complementary stacks tend to focus on broader neurological and metabolic support: 🔸 Cognitive & Neurological Support:

• Dihexa, Semax, Selank: Different mechanisms of neurological support that don’t overlap directly with IGF-1 pathway modulation.

🔸 IGF-1 / Growth Axis Adjacent:

• GH secretagogues (CJC-1295, Ipamorelin): Support the broader GH/IGF-1 axis that cGP interacts with downstream, though stacking rationale here is more theoretical than established.

Rationale: Because cGP’s mechanism is regulatory rather than stimulatory, stacking logic is less about “more of the same pathway” and more about complementary support across cognitive and metabolic systems.

Disclaimer: Do not rely on any dosing information provided, this is for educational and research only. Always double and triple check alternative references for education. Please consult with healthcare provider for your specific dosing and protocol if applicable.